Advantages of Prostate Artery Embolization with the Magellan Robotic System

Описание: Presentation on the role for robotics and Magellan Robotic System by Hansen Medical. Sandeep Bagla, MD, Interventional Radiologist (Inova Alexandria Hospital, Virginia) speaks about the current state of Prostatic Artery Embolization (PAE).

Learn more about Hansen robotics by visiting www.hansenmedical.com

Transcript (partial):
All right. Thank you very much for the invitation. I'm excited to speak about the role of robotics in Prostate Artery Embolization. So a couple of things I'm going to cover here. First, is just review the literature for PAE and describe a little bit about who's the candidate for the procedure, then focus on what the challenges are with the procedure, because think that's the main obstacle that we face with PAE. And then, the transition of the Magellan Robot into our current practice with PAE, and then what those actual advantages are over the traditional method. And I'll show some case examples.

So in terms of who is the candidate, there's really a few ways to break this down. The first is looking at what does the data support in terms of which patients to treat, who are poor traditionally urologic candidates, and let's talk about who's not really a candidate at all for PAE. So the data, when we look at a review article from 2014, this is published in CBIR, and it reviewed all the studies done up until mid last year. And as you'll see on the next slide, it looked at 562 studies through a PUBMED database study. They ended up narrowing it down to nine articles, in which they reviewed 706 patients that were actually included in the analysis.

There was some possible overlap of data from European studies, and there were no randomized control trials at that point published or studied longer than two years. All patients had moderate-to-severe symptoms in terms of their prostate enlargement, or BPH, and the mean age of the patient in these studies is, as you would expect, in the mid to late 60s to early 70s. When they took all the data together and they pulled it all together, they found out that although these patients started in the moderate-to-severe category, as you can see here in the dark blue line, this is an IPSS score, which is the severity of symptoms a man faces from their prostate enlargement.